Sparfloxacin worldwide in vitro literature: Isolate data available through 1994

Diagnostic Microbiology and Infectious Disease

Volumn 25, Issue 2, 1996, Pages 53-64

  Cohen, Michael A ^a,b   Yoder, Steven L ^a,b   Talbot, George H ^a,b  

^a PFIZER INC   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SPARFLOXACIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; CHLAMYDIACEAE; ENTEROCOCCUS; HAEMOPHILUS; HUMAN; LEGIONELLACEAE; MORAXELLA; MYCOBACTERIUM; MYCOPLASMA; NEISSERIACEAE; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS; UREAPLASMA;

EID: 0030175084     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(96)00121-6     Document Type: Article

References (114)

1. [1] Akaniro JC, Arguedas AG, Stutman HR, Vargas OM (1991) A comparison of the in vitro activity of sparfloxacin against isolates from cystic fibrosis patients. Abstr Annu Meet Am Soc Microbiol, Dallas, Abstr A-4, p. 1.
2. [2] Akaniro JC, Stutman HR, Arguedas AG, Vargas OM (1992) In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients. Antimicrob Agents Chemother 36:255-261.
3. [3] Alarcon T, Pita J, Lopez-Brea M, Piddock LJV (1993) High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain. J Antimicrob Chemother 32:605-609.
4. [4] Aldridge KE (1994) Increased activity of a new chlorofluoroquinolone, BAY y3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother 38:1671-1674.
5. [5] Ball P (1990) Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus anreus: Clinical significance and therapeutic approaches. J Antimicrob Chemother 26(Suppl F):165-179.
6. [6] Barrett MS, Jones RN, Erwin ME, Koontz FP (1992) CI-960 (PD 127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellulare complex, M. chelonae, and M. fortuitum. Diagn Microbiol Infect Dis 15:169-171.
7. [7] Barry AL (1990) In vitro activity of sparfloxacin (AT-4140, CI-978) compared to other fluoroquinolone agents and tentative disk susceptibility test criteria. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 1205, p. 287.
8. [8] Barry AL, Fuchs PC (1991) Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis 10:168-171.
9. [9] Barry AL, Fuchs PC (1991) In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother 35:955-960.
10. [10] Bauernfeind A (1993) Comparative in vitro activities of the new quinolone Bay y3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960, and CI-990. J Antimicrob Chemother 31:505-522.
11. [11] Bille J, Glauser MP (1990) In vitro activity of sparfloxacin (AT-4140) compared with that of three other quinolones against 433 clinical isolates. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 1199, p. 286.
12. [12] Borobio MV, del Carmen Conejo M, Ramirez E, Suarez AI, Perea EJ (1994) Comparative activities of eight quinolones against members of the Bacteroides fragilis group. Antimicrob Agents Chemother 38:1442-1445.
13. [13] Brown ST, Edwards FF, Bernard FM, Armstrong D (1991) Inhibition of Mycobacterium Avium Complex (MAC) by single agents and combinations. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Chicago, Abstr 674, p. 211.
14. [14] Brumfitt W, Hamilton-Miller JMT (1993) Incomplete cross-resistance between ciprofloxacin and sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin. J Antimicrob Chemother 31:610-612.
15. [15] Cantón E, Pemán J, Jimenez MT, Ramón MS, Gobernado M (1992) In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother 36:558-565.
16. [16] Canton R, Loza E, Martinez-Beltran J, Morosini MI, Negri C, Baquero F (1990) Sparfloxacin (AT-4140, RP-64206): the antimicrobial profile. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 1209, p. 287.
17. [17] Chaudhry AZ, Knapp CC, Sierra-Madero J, Washington JA (1990) Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother 34:1843-1845.
18. [18] Cherubin CE, Stratton CW (1994) Assessment of the bactericidal activity of sparfloxacin, ofloxacin, levofloxacin, and other fluoroquinolones compared with selected agents of proven efficacy against Listeria monocytogenes. Diagn Microbiol Infect Dis 20:21-25.
19. [19] Chin NX, Gu JW, Yu KW, Zhang YX, Neu HC (1991) In vitro activity of sparfloxacin. Antimicrob Agents Chemother 35:567-571.
20. [20] Clarke AM, Zemcov SJV (1990) In vitro activity of AT-4140. 3rd Intl Symposium on New Quinolones, Vancouver, Abstr 44.
21. [21] Cohen MA, Huband MD, Mailloux GB, Yoder SL, Roland GE, Heifetz CL (1991) In vitro activity of sparfloxacin (CI-978; AT-4140; PD 131501), a quinolone with high activity against gram-positive bacteria. Diagn Microbial Infect Dis 14:403-415.
22. [22] Cooper MA, Andrews JM, Ashby JP, Matthews RS, Wise R (1990) In vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother 26:667-676.
23. [23] Cooper MA, Baldwin D, Matthews RS, Andrews JM, Wise R (1991) In vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics. J Antimicrob Chemother 28:407-413.
24. [24] Daum TE, Shaberg DR, Terpenning MS, Sottile WS, Kauffman CA (1990) Increasing resistance of Staphylococcus aureus to ciprofloxacin. Antimicrob Agents Chemother 34:1862-1863.
25. [25] Dhople AM, Ibanez MA (1993) In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae. J Antimicrob Chemother 32:445-451.
26. [26] Doebelling BN, Pfaller MA, Bale MJ, Wenzel RP (1990) Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates. Eur J Clin Microbiol Infect Dis 9:298-301.
27. [27] Edelstein PH, Edelstein MAC, Weidenfeld J, Dorr MB (1990) In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 34: 2122-2127.
28. [28] Eliopoulos GM, Klimm K, Grayson ML (1990) In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent. Diagn Microbiol Infect Dis 13:345-348.
29. [29] Eron LJ, Harvey L, Hixon DL, Poretz DM (1985) Ciprofloxacin therapy of infections caused by Pseudamonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother 27:308-310.
30. [30] Focht J, Nosner K, Kresken M (1993) Sensitivity of community-acquired bacterial isolates to sparfloxacin in comparison with other antibiotics. Drugs 45 (Suppl 3): 152-156.
31. [31] Forstall GJ, Knapp CC, Washington JA (1991) Activity of new quinolones against ciprofloxacin-resistant staphylococci. Antimicrob Agents Chemother 35:1679-1681.
32. [32] Franzblau SG, White KE (1990) Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae. Antimicrob Agents Chemother 34:229-231.
33. [33] Freeman C, Robinson A, Cooper B, Mazens-Sullivan M, Quintiliani R, Nightingale C (1993) In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis 21:47-50.
34. [34] Fuchs PC, Barry AL, Pfaller MA, Allen SD, Gerlach EH (1991) Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother 35:764-766.
35. [35] García-Rodriguez JA, García Sánchez JE, Muñoz Bellido JL, Nebreda Mayoral T, García Sánchez E, García García I (1991) In vitro activity of 79 antimicrobial agents against Corynebacterium Group D2. Antimicrob Agents Chemother 35:2140-2143.
36. [36] Giamarellou H, Galanakis N, Dendrinos C, Stefanou J, Daphnis E, Daikos GK (1986) Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol 5:232-235.
37. [37] Gibb AP, Lewin CS, Garden OJ (1991) Development of quinolone resistance and multiple antibiotic resistance in Salmonella bovismorbificans in a pancreatic abscess. J Antimicrob Chemother 28:318-321.
38. [38] Goldstein EJC, Citron DM (1992) Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother 36:1158-1162.
39. [39] Gootz TD, Brighty KE, Anderson MR, Schmeider BJ, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR (1994) In vitro activity of CP-99,219, a novel 7-(3-azabicyclo-[3.1.0]hexyl) naphthyridone antimicrobial. Diagn Microbiol Infect Dis 19:235-243.
40. [40] Gransden WR, Warren CA, Phillips I, Hodges M, Barlow D (1990) Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet 335:51.
41. [41] Hindler JA, Sandoval FG, Young LS, Inderlied CB (1990) In vitro activity of sparfloxacin (AT-4140) and 13 other agents against clinical isolates including ciprofloxacin resistant (CIPR) strains of staphylococci, enterococci and gram-negative bacilli. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 1204, p. 287.
42. [42] Inderlied CB, Sandoval FG, Young LS (1990) Structure of 4-quinolones (4-Q's) and their activity vs the Mycobacterium avium complex (MAC). Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 1241, p. 25.
43. [43] John JF, Atkins LT, Maple PAH, Bratoeva M (1992) Activities of newer fluoroquinolones against Shigella sonnei. Antimicrob Agents Chemother 36:2346-2348.
44. [44] Joly-Guillou ML, Bergogne-Berezin E (1992) In-vitro activity of sparfloxacin, pefloxacin, ciprofloxacin and temafloxacin against clinical isolates of Acinetobacter spp. J Antimicrob Chemother 29:466-468.
45. [45] Jones RN (1992) Fluoroquinolone resistance: An evolving national problem or just a problem for some physicians? Diagn Microbiol Infect Dis 15:177-179.
46. [46] Jones RN, Barrett MS, Erwin ME, Briggs BM, Johnson DM (1991) In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds. Diagn Microbiol Infect Dis 14:319-330.
47. [47] Jorgensen JH, Maher LA, Ramirez PE (1991) Comparative activity of CI-960 with other orally administered antimicrobials against common bacterial respiratory pathogens. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Chicago, Abstr 1137, p. 288.
48. [48] Kaku M, Ishida K, Irifune K, et al. (1994) In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother 38:738-741.
49. [49] Kato M, Kuze F (1991) In vitro activities of a new quinolone derivative, sparfloxacin against Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium fortuitum. Chemother (Japan) 39(Suppl 4):101-106.
50. [50] Kawahara S, Sugano H, Kamisaka K, et al (1991) In vitro antimycobacterial activity of a new quinolone sparfloxacin. Jpn J Chest Dis 50:778-782.
51. [51] Kenney GE, Cartwright FD (1990) Selection of mutants of Mycoplasma hominis resistant to sparfloxacin. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 14, p. 89.
52. [52] Kenney GE, Cartwright FD (1991) Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin. Antimicrob Agents Chemother 35:587-589.
53. [53] Kimura M, Kishimoto T, Yoshihito N, Soejima R (1993) In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrob Agents Chemother 37:801-803.
54. [54] Kitsukawa K, Hara J, Saito A (1991) Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents. J Antimicrob Chemother 27:343-353.
55. [55] Klopman G, Wang S, Jacobs MR, Bajaksouzian S, Edmonds K, Ellner JJ (1993) Anti-Mycobacterium avium activity of quinolones: In vitro activities. Antimicrob Agents Chemother 37:1799-1806.
56. [56] Kojima T, Inoue M, Mitsuhashi S (1989) In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother 33:1980-1988.
57. [57] Kumamoto Y, Hirose T, Sato T (1990) Bacteriological and clinical efficacy of sparfloxacin on gonococcal and chlamydial infections of the genitourinary tract. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 1260, p. 296.
58. [58] LaBombardi VJ, Carter L, Cataldo-Caputzal L (1993) Sparfloxacin (CI-978), clinafloxacin (CI-960), and PD 131628: In vitro activity against Mycobacterium avium complex and M. tuberculosis. Abstr Annu Meet Am Soc Microbiol, Atlanta, Abstr C-126, p. 468.
59. [59] Lecso-Bornet M, Pierre J, Sarkis-Karam D, Lubera S, Bergogne-Berezin E (1992) Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrob Agents Chemother 36:669-671.
60. [60] LeFevre JC, Bauriaud R, Gaubert E, Escaffre MC, Lareng MB (1992) In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens. Chemother 38:303-307.
61. [61] Louie A, Baltch AL, Ritz WJ, Smith RP (1991) Comparative in vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD 131501) and reference antimicrobial agents. J Antimicrob Chemother 27:793-799.
62. [62] Louie A, Baltch AL, Ritz WJ, Smith RP (1991) In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria. Chemother 37:275-282.
63. [63] Malmborg A-S, Ahlen S (1993) In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens. Chemother 39:32-35.
64. [64] Martin DH, Cammarata CL, Grubb DS (1991) In vitro activity of sparfloxacin, (CI-978, AT-4140), ofloxacin, doxycycline, and tetracycline versus genital tract mycoplasmas and Chlamydia trachomatis. Eur J Clin Microbiol Infect Dis Special Issue 563-564.
65. [65] Miyamato T, Matsumoto J, Chiba K, et al (1990) Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. J Med Chem 33:1645-1656.
66. [66] Murray PR, Bratcher JL, Niles AC, Hampton CM (1993) In vitro activity of nine fluoroquinolone antibiotics against 200 strains of Enterococci. Diagn Microbiol Infect Dis 16:83-85.
67. [67] Nakamura S, Minami A, Nakata K, et al (1989) In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother 33:1167-1173.
68. [68] Nakata K, Hiroshi M, Fujii A, Soichi A, Keiichi U, Sadao K (1992) In vitro and in vivo activity of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis. Antimicrob Agents Chemother 36:188-190.
69. [69] Nishino T (1990) Sparfloxacin (AT-4140). In, New drug symposium (2) - antibacterial activity. 38th General Meeting of West Japan Branch, Japan Society of Chemotherapy Proceedings Nagara, p. 35.
70. [70] Nishino T, Otsuki M, Nakamura M, Wano T (1991) In vitro and in vivo antibacterial activities of sparfloxacin, a new quinolone. Chemotherapy (Tokyo) 39(Suppl 4):59-77.
71. [71] Nordmann P, Ronco E (1992) In-vitro antimicrobial susceptibility of Rhodococcus equi. J Antimicrob Chemother 29:383-393.
72. [72] Norris SJ (1990) Activities of cephalosporins and quinolones against Treponema pallidum subsp. pallidum (Nichols) in an in vitro culture system. Abstr Annu Meet Am Soc Microbiol, Anaheim, Abstr A-6, p. 2.
73. [73] Ogle JW, Reller LB, Vasil ML (1988) Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: Proof provided by typing with a DNA probe. J Infect Dis 157:743-748.
74. [74] Oh H, Bowie WR (1990) In vitro activity of sparfloxacin and other quinolones against Chlamydia trachomatis. 3rd International Symposium on New Quinolones, Vancouver, Abstr 287, p. 357.
75. [75] Ohye R, Higa H, Vogt R, Washington JA, Doyle L, Sayers D, Halpin TJ (1994) Decreased susceptibility of Neisseria gonorrhoeae to fluoroquinolones - Ohio and Hawaii, 1992-1994. Morb Mort Wkly Rep 43:325-327.
76. [76] Orfila J, Haider F, Eb F (1990) In vitro susceptibility of Chlamydia pneumoniae (IOL 207) to a new fluoroquinolone, sparfloxacin, compared with different other molecules. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 18, p. 89.
77. [77] Pankuch GA, Jacobs MR, Applebaum PC (1995) Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 35:230-232.
78. [78] Pearlman M, Faro S, Riddle G (1990) In vitro activity of a new quinolone, sparfloxacin (AT-4140), against clinical isolates of Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma urealyticum. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 23, p. 90.
79. [79] Peterson LR, Quick JN, Jensen B, et al (1990) Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Arch Int Med 150:2151-2155.
80. [80] Piddock LJV, Zhu M, Hall MC, Wise R (1990) The interaction of sparfloxacin with gram-negative and gram-positive bacteria. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 1206, p. 287.
81. [81] Preston M, Simor A, Fuller S, Jarrett S, Walmsley S, Patton C (1990) Comparative in vitro activity of 13 antibiotics against Campylobacter upsaliensis. Abstr Annu Meet Am Soc Microbiol, Anaheim, Abstr A-32, p. 6.
82. [82] Qadri SMH, Ueno Y, Burns JJ, Almodovar E, Rabea N (1992) In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone. Chemother 38:99-106.
83. [83] Raoult D, Bres P, Drancourt M, Vestris G (1991) In vitro susceptibilities of Coxiella burnetii, Rickettsia rickettsii, and Rickettsia conorii to the fluoroquinolone sparfloxacin. Antimicrob Agents Chemother 35:88-91.
84. [84] Rastogi N, Goh KS (1991) In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 35:1933-1936.
85. [85] Rastogi N, Labrousse V, Goh KS, Carvalho de Sousa JP (1991) Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. Antimicrob Agents Chemother 35:2473-2480.
86. [86] Renaudin H, Tully JG, Bebear C (1992) In vitro susceptibilities of Mycoplasma genitalium to antibiotics. Antimicrob Agents Chemother 36:870-872.
87. [87] Roblin PM, Hammerschlag MR (1990) In vitro activity of sparfloxacin (CI-978, AT-4140) and two other quinolones against Chlamydia trachomatis and Chlamydia pneumoniae. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 22, p. 90.
88. [88] Rohner P, Peebo M, Lew DP, Auckenthaler R, Pechère JC (1992) Comparative in vitro activity of new quinolones against clinical isolates and resistant mutants. J Antimicrob Chemother 29:41-48.
89. [89] Rolston KVI, Messer M, Ho DH (1990) Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer. Antimicrob Agents Chemother 34:1812-1813.
90. [90] Rolston KVI, Nguyen H, Messer M, LeBlanc B, Ho DH, Bodey GP (1990) In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. Antimicrob Agents Chemother 34:2263-2266.
91. [91] Rotstein C, Amsterdam D, Beam, Jr, TR, Mandell LA, Gorzynski EA (1993) In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of Gram-positive cocci. Diagn Microbiol Infect Dis 17:85-91.
92. [92] Rubinstein E, Lang R, Sasha B, et al (1991) In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 35:1925-1927.
93. [93] Rudrick JT, Ferrigno SR, Gee SL (1991) In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci. Diagn Microbiol Infect Dis 14:355-360.
94. [94] Simor AE, Fuller SA, Low DE (1990) Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens. Antimicrob Agents Chemother 34:2283-2286.
95. [95] Skinner PS, Furney SK, Kleinert DA, Orme IM (1995) Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 39:750-753.
96. [96] Smith KR, Cobbs CG (1992) In vitro activity of AT-4140 (sparfloxacin) and three other fluoroquinolones against methicillin resistant Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis 11:55-58.
97. [97] Talbot H, Romanowski B (1991) In vitro activities of sparfloxacin, ceftriaxone, penicillin, tetracycline and doxycycline against Chlamydia trachomatis and Neisseria gonorrhoeae. Can J Infect Dis 2:1-6.
98. [98] Tanaka M, Hoshino K, Ishida H, Sato K, Hayakawa I, Osada Y (1993) Antimicrobial activity of DV-7751a, a new fluoroquinolone. Antimicrob Agents Chemother 37: 2112-2118.
99. [99] Thomson KS, Sanders CC, Hayden ME (1991) In vitro studies with five quinolones: Evidence for changes in relative potency as quinolone resistance rises. Antimicrob Agents Chemother 35:2329-2334.
100. [100] Thomson KS, Schadow KH, Hayden ME, Sanders CC, Sanders, Jr. WE (1990) In vitro activity of CI-960, PD 131628, ofloxacin and ciprofloxacin against bacteria with varying levels of resistance to ciprofloxacin. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 376, p. 149.
101. [101] Tomioka H, Sato K, Saito H (1993) Antimicrobial activity of new quinolones against Mycobacterium avium and Mycobacterium intracellulare determined by the dilution methods using 7H11 agar and Ogawa egg media. Kekkaku 68:367-370.
102. [102] Truffot-Pernot C, Grosset BJJ (1991) In vitro activity of sparfloxacin against tuberculosis and non-tuberculosis Mycobacteria. Eur J Clin Micro Infect Dis Special Issue 561-562.
103. [103] Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K (1994) A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: Implications for therapy. Antimicrob Agents Chemother 38:624-627.
104. [104] Visser MR, Hoepelman IM, Beumer H, Rozenberg-Arska M, Verhoef J (1991) Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP64206), a new quinolone. Antimicrob Agents Chemother 35:858-868.
105. [105] Voutsinas D, Xirouchaki E, Giamarellou H (1990) Comparative in vitro activity of sparfloxacin (AT-4140, RP 64206-SPAR) against 276 multiresistant clinical isolates. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 1200, p. 286.
106. [106] Wagenvoort JHT, van der Willigen AH, van Noort JA (1986) Decreased sensitivity of Neisseria gonorrhoeae to quinolone compounds. Eur J Clin Microbiol 5:685.
107. [107] Waites KB, Duffy LB, Schmid T, Crabb D, Pate MS, Cassell GH (1991) In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrob Agents Chemother 35:1181-1185.
108. [108] Wanger AR, Singh KV, Murray BE (1990) In vitro activity of sparfloxacin against resistant enterococci and staphylococci. Prog Abstr Intersci Conf Antimicrob Agents Chemother, Atlanta, Abstr 1202, p. 286.
109. [109] Wexler HM, Molitoris E, Finegold SM (1992) In vitro activities of three of the newer quinolones against anaerobic bacteria. Antimicrob Agents Chemother 36:239-243.
110. [110] Witzig RS, Franzblau SG (1993) Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid. Antimicrob Agents Chemother 37:1997-1999.
111. [111] Yajko DM, Sanders CA, Nassos PS, Hadley WK (1990) In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. Antimicrob Agents Chemother 34:2442-2444.
112. [112] Yamamoto T, Echeverria P, Yokata T (1992) Drug resistance and adherence to human intestines of enteroaggregative Escherichia coli. J Infect Dis 165:744-749.
113. [113] Yamane N, Jones RN (1991) In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin. Diagn Microbiol Infect Dis 14:337-345.
114. [114] Yew WW, Piddock LJV, Li MSK, Lyon D, Chan CY, Cheng AFB (1994) In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 34:343-351.